Dimensional Fund Advisors LP grew its position in shares of Coty Inc. (NYSE:COTY – Free Report) by 10.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,387,661 shares of the company’s stock after buying an additional 890,626 shares during the period. Dimensional Fund Advisors LP owned approximately 1.08% of Coty worth $94,068,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Quent Capital LLC increased its position in Coty by 1,448.8% during the second quarter. Quent Capital LLC now owns 5,142 shares of the company’s stock worth $52,000 after acquiring an additional 4,810 shares during the period. WealthShield Partners LLC acquired a new stake in shares of Coty in the second quarter valued at approximately $100,000. Fifth Third Wealth Advisors LLC bought a new stake in shares of Coty in the second quarter valued at approximately $107,000. EntryPoint Capital LLC grew its position in Coty by 260.4% during the first quarter. EntryPoint Capital LLC now owns 11,652 shares of the company’s stock worth $139,000 after buying an additional 8,419 shares in the last quarter. Finally, Norden Group LLC acquired a new stake in Coty during the first quarter worth approximately $146,000. Institutional investors and hedge funds own 42.36% of the company’s stock.
Coty Stock Performance
COTY opened at $9.29 on Wednesday. The company’s 50 day moving average price is $9.45 and its two-hundred day moving average price is $10.34. The firm has a market capitalization of $8.06 billion, a price-to-earnings ratio of 40.39, a PEG ratio of 0.66 and a beta of 1.89. Coty Inc. has a fifty-two week low of $8.66 and a fifty-two week high of $13.30. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.75 and a quick ratio of 0.46.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on the company. Barclays cut their target price on Coty from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Thursday, August 22nd. Wells Fargo & Company cut their price target on shares of Coty from $12.00 to $11.00 and set an “equal weight” rating for the company in a report on Wednesday, July 10th. Stifel Nicolaus lowered their price objective on shares of Coty from $12.00 to $11.00 and set a “hold” rating for the company in a research report on Wednesday, August 21st. Citigroup decreased their price target on Coty from $12.00 to $11.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. Finally, Evercore ISI restated an “outperform” rating and set a $15.00 price objective on shares of Coty in a research report on Wednesday, August 21st. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.85.
View Our Latest Stock Report on Coty
Coty Profile
Coty Inc, together with its subsidiaries, manufactures, markets, distributes, and sells beauty products worldwide. It operates through Prestige and Consumer Beauty segments. The company provides fragrance, color cosmetics, and skin and body care products. It offers Prestige segment products primarily through prestige retailers, including perfumeries, department stores, e-retailers, direct-to-consumer websites, and duty-free shops under the Burberry, Calvin Klein, Chloe, Davidoff, Escada, Gucci, Hugo Boss, Jil Sander, Joop!, Kylie Jenner, Lancaster, Marc Jacobs, Miu Miu, Orveda, philosophy, SKKN BY KIM, and Tiffany & Co brands.
Featured Articles
- Five stocks we like better than Coty
- What is the Shanghai Stock Exchange Composite Index?
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Airline Stocks – Top Airline Stocks to Buy Now
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- The 3 Best Fintech Stocks to Buy Now
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Coty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coty and related companies with MarketBeat.com's FREE daily email newsletter.